This is the authors' abstract. We don't add key points for this paper.
Vancomycin, an antibiotic isolated from Streptomyces ~rientalis, was developed to treat staphylococcal infections resistant to the penicillins. However, because intravenous administration was associated with venous irritation, vancomycin was largely replaced by semisynthetic penicillins. Recently, intravenously administered vancomycin has come into increasing use, and its indications now include infections caused by Staphylococcus epidermidis and resistant Staphylococcus aureus.1 Vancomycin has become an important antibiotic for use in premature newborn infants, because S. epidermidis is the most common nosocomial infection in the neonatal intensive care unit. 2,3 Adverse reactions attributed to vaneomycin have been described in adults and children, but not in newborn infants. We report two newborn infants who had shock and rash after receiving vancomycin; these reactions were identified by tt~e Pediatric Drug Surveillance (PeDS) Program at the Children's Hospital, Boston. 4
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Lacouture et al. (1987) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: